The Board of Morepen Laboratories at its meeting held on 12 May 2025 has noted the decision of the Board of Directors of Morepen Medipath (formerly known as Morepen Medtech), a subsidiary of the Company, to incorporate a Wholly Owned Subsidiary in the mainland at Dubai, United Arab Emirates. The incorporation of the wholly owned subsidiary is intended to expand both the Business-to-Consumer (B2C) and Business-to-Business (B2B) customer segments and to provide greater access to the medical device business.Upon incorporation, the proposed company will become a step-down subsidiary of Morepen Laboratories. Powered by Capital Market - Live News

Net profit of Morepen Laboratories declined 28.15% to Rs 20.32 crore in the quarter ended March 2025 as against Rs 28.28 crore during the previous quarter ended March 2024. Sales rose 10.11% to Rs 465.85 crore in the quarter ended March 2025 as against Rs 423.07 crore during the previous quarter ended March 2024.For the full year,net profit rose 22.73% to Rs 118.02 crore in the year ended March 2025 as against Rs 96.16 crore during the previous year ended March 2024. Sales rose 7.17% to Rs 1811.58 crore in the year ended March 2025 as against Rs 1690.43 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales465.85423.07 10 1811.581690.43 7 OPM %9.0711.44 -9.619.38 - PBDT42.1851.83 -19 184.09168.89 9 PBT25.7142.20 -39 155.11135.42 15 NP20.3228.28 -28 118.0296.16 23 Powered by Capital Market - Live News

Morepen Laboratories announced that the Board of Directors of the Company at its meeting held on 12 May 2025, has recommended a Final Dividend of Rs.0.20 per share (i.e.10%), subject to the approval of the shareholders.Powered by Capital Market - Live News

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 12 May 2025.Powered by Capital Market - Live News

Morepen Laboratories has got clearance from Subject Expert Committee (SEC) of Central Drugs Standard Control Organization (CDSCO) to conduct Bioequivalence (BE) studies for Resmetirom 60 mg, 80 mg and 100 mg tablets as per the protocol submitted. This will be followed by clinical trials as per approved protocols. Resmetirom is a highly promising therapy under development for non-alcoholic steatohepatitis (`NASH`), a serious form of non-alcoholic fatty liver disease (NAFLD) characterized by inflammation, liver damage, and fat accumulation in the liver, potentially leading to scarring (fibrosis), cirrhosis, and even liver cancer. It is often associated with obesity, metabolic syndrome, and type 2 diabetes, and while it can be a silent disease in the early stages, it can progress to severe liver damage if left untreated. As one of the first Indian companies to foray into this therapeutic area, Morepen is strategically positioned to serve both domestic and international markets and is also evaluating out-licencing opportunities with potential marketing partners.Powered by Capital Market - Live News